Daiwa Securities Group
CGEM icon

Daiwa Securities Group’s Cullinan Oncology CGEM Stock Holding History

Daiwa Securities Group’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-218
Closed -$2K – 1235
2025
Q4 		$2K Hold
218
– – ﹤0.01% 1297
2025
Q3 		$1K Hold
218
– – ﹤0.01% 1304
2025
Q2 		$2K Hold
218
– – ﹤0.01% 1207
2025
Q1 		$2K Hold
218
– – ﹤0.01% 1177
2024
Q4 		$3K Hold
218
– – ﹤0.01% 1188
2024
Q3 		$4K Hold
218
– – ﹤0.01% 1178
2024
Q2 		$4K Buy
218
+91
+72% +$1.94K ﹤0.01% 1208
2024
Q1 		$2K Hold
127
– – ﹤0.01% 1262
2023
Q4 		$1K Hold
127
– – ﹤0.01% 1291
2023
Q3 		$1K Hold
127
– – ﹤0.01% 1241
2023
Q2 		$1K Hold
127
– – ﹤0.01% 1262
2023
Q1 		$1K Hold
127
– – ﹤0.01% 1244
2022
Q4 		$1K Hold
127
– – ﹤0.01% 1262
2022
Q3 		$2K Hold
127
– – ﹤0.01% 1218
2022
Q2 		$2K Hold
127
– – ﹤0.01% 1227
2022
Q1 		$1K Hold
127
– – ﹤0.01% 1297
2021
Q4 		$2K Buy
+127
New +$2.53K ﹤0.01% 1276

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Daiwa Securities Group's CGEM Position: Q1 2026 in Review

Daiwa Securities Group sold out of Cullinan Oncology (CGEM) in Q1 2026, closing a stake of 218 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in CGEM in Q4 2021 and held it in 17 quarters. The position peaked at $4K in Q3 2024. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Daiwa Securities Group reported no remaining Cullinan Oncology position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 218 Cullinan Oncology shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in Cullinan Oncology in Q4 2021 and held it in 17 quarters.
  • Daiwa Securities Group's Cullinan Oncology position peaked at $4K in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.